The collaboration aims to create an integrated discovery-to-manufacturing ecosystem that accelerates development timelines, and provides highest quality cell therapies within a cost-effective infrastructure.

Strategic partnership with FSG_Labs intended to bring future T-CURX non-viral CAR-T therapies to Dubai and to the Middle East region.

The Series A syndicate was led by BiomedVC and included Bayern Kapital, HighLight Capital (HLC), and i&iBio Fund, as additional investors along with existing and new individual investors.

The agreement provides T-CURX with access to the Flowfect^® cellular engineering technology. By combining the Flowfect Tx^® platform with its proprietary transposon gene transfer technology, T-CURX seeks to overcome the hurdles in cell therapy scale-up and and accelerate timelines.

The JP Morgan Healthcare conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

The appointment of Hans-Peter Gerber as Chairman and Bernd Eschgfäller as independent Board member strengthens T-CURX’s Board to accelerate the commercialization of its proprietary CAR-T technologies and CAR-T pipeline programs.

Ulf Grawunder brings a strong track record in founding and building biopharmaceutical companies all the way toward a successful exit. His previous positions include roles as CEO at 4-Antibody AG, acquired by Agenus in 2012, and NBE-Therapeutics, acquired by Boehringer Ingelheim in 2021.

The project is aimed to develop novel super-resolution microscopy based technologies allowing a personalized assessment of eligibility of tumor patients with very low level expression of tumor associated antigens for CAR-T cell therapies.

SaxoCell is developing new ways to produce gene and cell therapies safely, efficiently and affordably. The aim is to make so-called “living drugs” available for clinical application on a large scale – and thus strengthen healthcare and regional value creation.

The objective of the T2EVOLVE project is to establish standards for pre-clinical development, manufacturing and clinical use of CAR-T und TCR-T immunotherapies. The consortium aims to boost Europe to the forefront of immunotherapy.

The scope of the license agreement provides T-CURX with a broad IPR basis to commercialize an attractive and competitive pipeline of CAR-T cell therapies in hematologic and solid tumor indications.

First multiple myeloma patient dosed with with a SLAM-F7/CS1 specific CAR-T cell product employing T-CURX' proprietary Sleeping Beauty transposon gene-transfer technology.

The vision of imSAVAR (Immune Safety Avatar) is to develop a platform for integrated non-clinical assessments of the safety and efficacy of immunomodulatory therapies. The resulting platform will improve the prediction of the transferability of safety and efficacy of immunomodulators from pre-clinical models to first-in-human (FiH) studies.

The European Commission selected the project CARAMBA (“SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma – a rare hematologic disease”) within the scope of its Research and Innovation action programme, Horizon2020.

The founding team of T-CURX include Prof. Michael Hudecek, MD (University Clinics of Würzburg, Germany), Prof. Christoph Rader, PhD (The Scripps Research Institute, Jupiter, FL, USA) and Dr. Ulf Grawunder, PhD (previously CEO of NBE-Therapeutics, Basel, Switzerland).